Combined loss of the BH3-only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic mice

Cell Death and Differentiation

Volumn 22, Issue 9, 2015, Pages 1477-1488

  Woess, C ^a   Tuzlak, S ^a   Labi, V ^a   Drach, M ^b,c   Bertele, D ^d   Schneider, P ^e   Villunger, A ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATACICEPT; B CELL ACTIVATING FACTOR; BH3 PROTEIN; BIM PROTEIN; BMF PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BAX PROTEIN (53-86); BCL2L11 PROTEIN, MOUSE; BMF PROTEIN, MOUSE; HYBRID PROTEIN; MEMBRANE PROTEIN; ONCOPROTEIN; PEPTIDE FRAGMENT; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TACI RECEPTOR-IGG FC FRAGMENT FUSION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPLEEN CELL; ANIMAL; C57BL MOUSE; CYTOLOGY; GENETICS; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

MURINAE; MUS; MUS MUSCULUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTES; BCL-2-LIKE PROTEIN 11; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 84938965097     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.8     Document Type: Article

References (54)

1. von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010; 11: 14-20.
2. Herzog S, Jumaa H. Self-recognition and clonal selection: autoreactivity drives the generation of B cells. Curr Opin Immunol 2012; 24: 166-172.
3. Mackay F, Figgett WA, Saulep D, Lepage M, Hibbs ML. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 2010; 237: 205-225.
4. Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol 2008; 20: 149-157.
5. Cerutti A, Cols M, Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 2013; 13: 118-132.
6. Kulathu Y, Grothe G, Reth M. Autoinhibition and adapter function of Syk. Immunol Rev 2009; 232: 286-299.
7. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M et al. An essential role for BAFF in the normal development of B cells through a BCMAindependent pathway. Science 2001; 16: 2111-2114.
8. Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 2001; 194: 1691-1697.
9. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cellactivating factor (BAFF) receptor-dependent and-independent roles for BAFF in B cell physiology. J Immunol 2004; 173: 2245-2252.
10. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2108-2111.
11. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009; 9: 491-502.
12. Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004; 24: 997-1006.
13. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008; 111: 2755-2764.
14. Yan M, Brady JR, Chan B, Lee WP, Hsu B, Harless S et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B-cell deficiency. Curr Biol 2001; 11: 1547-1552.
15. Salzer U, Chapel HM, Webster AD, Pan-Hammarstrom Q, Schmitt-Graeff A, Schlesier M et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005; 37: 820-828.
16. Warnatz K, Salzer U, Rizzi M, Fischer B, Gutenberger S, Bohm J et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci USA 2009; 106: 13945-13950.
17. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013; 24: 203-215.
18. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-1710.
19. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192: 953-964.
20. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002; 168: 5993-5996.
21. Woodland RT, Fox CJ, Schmidt MR, Hammerman PS, Opferman JT, Korsmeyer SJ et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 2008; 111: 750-760.
22. Otipoby KL, Sasaki Y, Schmidt-Supprian M, Patke A, Gareus R, Pasparakis M et al. BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells. Proc Natl Acad Sci USA 2008; 105: 12435-12438.
23. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75: 229-240.
24. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307: 1101-1104.
25. Ottina E, Grespi F, Tischner D, Soratroi C, Geley S, Ploner A et al. Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood 2012; 119: 6032-6042.
26. Tischner D, Woess C, Ottina E, Villunger A. Bcl-2-regulated cell death signalling in the prevention of autoimmunity. Cell Death Dis 2010; 1: e48.
27. Amanna IJ, Dingwall JP, Hayes CE. Enforced bcl-xL gene expression restored splenic B lymphocyte development in BAFF-R mutant mice. J Immunol 2003; 170: 4593-4600.
28. Peperzak V, Vikstrom I,Walker J, Glaser SP, LePage M, Coquery CM et al. Mcl-1 is essential for the survival of plasma cells. Nat Immunol 2013; 14: 290-297.
29. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005; 202: 1363-1374.
30. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441-453.
31. Oliver PM, Vass T, Kappler J, Marrack P. Loss of the proapoptotic protein, Bim, breaks B cell anergy. J Exp Med 2006; 203: 731-741.
32. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med 2003; 198: 1119-1126.
33. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Köntgen F et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-1738.
34. Pinon JD, Labi V, Egle A, Villunger A. Bim and Bmf in tissue homeostasis and malignant disease. Oncogene 2008; 27: S41-S52.
35. Eldering E, Spek CA, Aberson HL, Grummels A, Derks IA, de Vos AF et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res 2003; 31: e153.
36. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2013; 15: 49-63.
37. Baumgartner F, Woess C, Pedit V, Tzankov A, Labi V, Villunger A. Minor cell-death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf. Oncogene 2013; 32: 621-630.
38. Labi V, Erlacher M, Kiessling S, Manzl C, Frenzel A, O'Reilly L et al. Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development. J Exp Med 2008; 205: 641-655.
39. Erlacher M, Labi V, Manzl C, Bock G, Tzankov A, Hacker G et al. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med 2006; 203: 2939-2951.
40. Ranger AM, Zha J, Harada H, Datta SR, Danial NN, Gilmore AP et al. Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9324-9329.
41. Pelletier M, Thompson JS, Qian F, Bixler SA, Gong DH, Cachero T et al. Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J Biol Chem 2003; 278: 33127-33133.
42. Ng LG, Ng CH, Woehl B, Sutherland AP, Huo J, Xu S et al. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur J Immunol 2006; 36: 1837-1846.
43. Egle A, Harris AW, Bath ML, O'Reilly L, Cory S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 2004; 103: 2276-2283.
44. Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong CH et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119: 5807-5816.
45. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
46. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 1999; 96: 14943-14948.
47. Grespi F, Soratroi C, Krumschnabel G, Sohm B, Ploner C, Geley S et al. BH3-only protein Bmf mediates apoptosis upon inhibition of CAP-dependent protein synthesis. Cell Death Differ 2010; 17: 1672-1683.
48. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
49. Rowland SL, Leahy KF, Halverson R, Torres RM, Pelanda R. BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J Immunol 2010; 185: 4570-4581.
50. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003; 426: 671-676.
51. Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYCdriven B-cell lymphomas. Blood 2013; 121: 2964-2974.
52. Labi V, Woess C, Tuzlak S, Erlacher M, Bouillet P, Strasser A et al. Deregulated cell death and lymphocyte homeostasis cause premature lethality in mice lacking the BH3-only proteins Bim and Bmf. Blood 2014; 123: 2652-2662.
53. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ et al. p53-and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038.
54. Tischner D, Wiegers GJ, Fiegl H, Drach M, Villunger A. Mutual antagonism of TGF-beta and Interleukin-2 in cell survival and lineage commitment of induced regulatory T cells. Cell Death Differ 2012; 19: 1277-1287.